Evidence map›Paper›PMID 34868052›Full record

ArticleFrontiers in immunology2021

MG1141A as a Highly Potent Monoclonal Neutralizing Antibody Against SARS-CoV-2 Variants.

Sua Lee, Shina Jang, Jihoon Kang, Soo Bin Park, Young Woo Han, Hyemi Nam, Munkyung Kim, Jeewon Lee, Ki Joon Cho, Jeonghun Kim and 9 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.1field-weighted citation impact, top 50% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 3 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 4 institutions in 2 countries.

Sua LeeDepartment of Protein Engineering, Mogam Institute for Biomedical Research, Yongin, South Korea.
Shina JangDepartment of Protein Engineering, Mogam Institute for Biomedical Research, Yongin, South Korea.
Jihoon KangDepartment of Protein Engineering, Mogam Institute for Biomedical Research, Yongin, South Korea.
Soo Bin ParkDepartment of Protein Engineering, Mogam Institute for Biomedical Research, Yongin, South Korea.
Young Woo HanDepartment of Infectious Disease Research, Mogam Institute for Biomedical Research, Yongin, South Korea.
Hyemi NamDepartment of Target ID & Assay Development, Mogam Institute for Biomedical Research, Yongin, South Korea.
Munkyung KimDepartment of Target ID & Assay Development, Mogam Institute for Biomedical Research, Yongin, South Korea.
Jeewon LeeDepartment of Target ID & Assay Development, Mogam Institute for Biomedical Research, Yongin, South Korea.
Ki Joon ChoDepartment of Protein Engineering, Mogam Institute for Biomedical Research, Yongin, South Korea.
Jeonghun KimDepartment of Microbiology, Institute for Viral Diseases, Korea University College of Medicine, Seoul, South Korea.
Miyoung OhDepartment of Protein Engineering, Mogam Institute for Biomedical Research, Yongin, South Korea.
Jihye RyuDepartment of Translational Research, Mogam Institute for Biomedical Research, Yongin, South Korea.
Jong Hyeon SeokDepartment of Microbiology, Institute for Viral Diseases, Korea University College of Medicine, Seoul, South Korea.
Yunhwa KimDepartment of Microbiology, College of Medicine, Yeungnam University, Daegu, South Korea.
Jee-Boong LeeDepartment of Target ID & Assay Development, Mogam Institute for Biomedical Research, Yongin, South Korea.
Man-Seong ParkDepartment of Microbiology, Institute for Viral Diseases, Korea University College of Medicine, Seoul, South Korea.
Yong-Sung KimDepartment of Molecular Science and Technology, Ajou University, Suwon, South Korea.
Hosun ParkDepartment of Microbiology, College of Medicine, Yeungnam University, Daegu, South Korea.
Dong-Sik KimDepartment of Protein Engineering, Mogam Institute for Biomedical Research, Yongin, South Korea.
Target (United States) · USKorea University · KRYeungnam University · KRAjou University · KR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Since the coronavirus disease outbreak in 2019, several antibody therapeutics have been developed to treat severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections. Antibody therapeutics are effective in neutralizing the virus and reducing hospitalization in patients with mild and moderate infections. These therapeutics target the spike protein of SARS-CoV-2; however, emerging mutations in this protein reduce their efficiency. In this study, we developed a universal SARS-CoV-2 neutralizing antibody. We generated a humanized monoclonal antibody, MG1141A, against the receptor-binding domain of the spike protein through traditional mouse immunization. We confirmed that MG1141A could effectively neutralize live viruses, with an EC

Indexed as

AnimalsAntibodies, MonoclonalAntibodies, NeutralizingAntibodies, ViralAntibody AffinityComplementarity Determining RegionsCOVID-19EpitopesHumansImmunizationMiceMolecular Docking SimulationProtein Interaction Domains and MotifsReceptors, IgGSARS-CoV-2Spike Glycoprotein, CoronavirusAntibodies, MonoclonalAntibodies, NeutralizingAntibodies, ViralComplementarity Determining RegionsEpitopesMG1141AReceptors, IgGSpike Glycoprotein, Coronavirusspike protein, SARS-CoV-2MG1141Amonoclonal antibodyoutbreakSARS-CoV-2spike protein

Identifiers

PMID34868052
PMCPMC8637776
OpenAlexW3213066087

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.